Novartis AG ADR (NVS)vsTeleflex Incorporated (TFX)
NVS
Novartis AG ADR
$156.08
+3.22%
HEALTHCARE · Cap: $286.29B
TFX
Teleflex Incorporated
$138.98
-0.01%
HEALTHCARE · Cap: $5.53B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2415% more annual revenue ($56.69B vs $2.25B). NVS leads profitability with a 22.5% profit margin vs -45.8%. TFX appears more attractively valued with a PEG of 0.16. TFX earns a higher WallStSmart Score of 52/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TFX
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.2%
Fair Value
$93.84
Current Price
$156.08
$62.24 premium
Margin of Safety
+9.1%
Fair Value
$117.70
Current Price
$138.98
$21.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 28.9% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Distress zone — elevated risk
ROE of -32.7% — below average capital efficiency
Earnings declined 17.3%
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : TFX
The strongest argument for TFX centers on PEG Ratio, Price/Book, Revenue Growth. Revenue growth of 28.9% demonstrates continued momentum. PEG of 0.16 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : TFX
The primary concerns for TFX are Altman Z-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
NVS profiles as a value stock while TFX is a growth play — different risk/reward profiles.
TFX carries more volatility with a beta of 0.83 — expect wider price swings.
TFX is growing revenue faster at 28.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
TFX scores higher overall (52/100 vs 51/100) and 28.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Teleflex Incorporated
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?